Actinium Pharmaceuticals (NYSE:ATNM) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a report released on Friday morning,Benzinga reports. They currently have a $4.00 price objective on the stock.

ATNM has been the topic of a number of other research reports. StockNews.com downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. B. Riley lowered shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $16.00 to $2.00 in a report on Wednesday, August 7th. Finally, Maxim Group lowered their price target on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $11.40.

Actinium Pharmaceuticals Trading Down 9.1 %

Shares of Actinium Pharmaceuticals stock opened at $1.50 on Friday. The stock has a market capitalization of $46.80 million, a PE ratio of -1.08 and a beta of 0.14. The business’s fifty day simple moving average is $1.79. Actinium Pharmaceuticals has a 1 year low of $1.33 and a 1 year high of $10.24.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Interchange Capital Partners LLC purchased a new position in shares of Actinium Pharmaceuticals in the third quarter worth about $37,000. Barclays PLC boosted its position in shares of Actinium Pharmaceuticals by 323.0% during the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after acquiring an additional 32,784 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Actinium Pharmaceuticals in the second quarter valued at about $92,000. Wellington Management Group LLP acquired a new stake in Actinium Pharmaceuticals during the third quarter worth about $112,000. Finally, Creative Financial Designs Inc. ADV increased its holdings in shares of Actinium Pharmaceuticals by 183.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 63,785 shares of the company’s stock worth $120,000 after buying an additional 41,250 shares during the last quarter. 27.50% of the stock is currently owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).